We expect Indian Pharma to report 9% y-o-y revenue growth and 100bps margin drop ... For Sun Pharma, specialty launch spend remains the key. ... for the overall industry (213 in Q2FY19 vs 208 in Q1FY19) and Indian companies.
Read more: Pharmaceuticals Q2FY19 preview: Quarter likely to see muted performance